RT Journal Article
SR Electronic
T1 Efficacy and Safety of Lenvatinib for Patients With Advanced Hepatocellular Carcinoma: A Retrospective, Real-world Study Conducted in Japan
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 173
OP 183
DO 10.21873/anticanres.15471
VO 42
IS 1
A1 SHIMOZATO, NAOTAKA
A1 NAMISAKI, TADASHI
A1 OKANO, AKIHIRO
A1 OHANA, MASAYA
A1 KINOSHITA, DAISUKE
A1 KAWASAKI, TOSHIHIKO
A1 AIHARA, YOSUKE
A1 NAKATANI, TOSHIYA
A1 KINOSHITA, HIROKI
A1 ANN, TATSUICHI
A1 SAITO, KO
A1 YOSHIDA, MOTOYUKI
A1 YOSHIJI, HITOSHI
YR 2022
UL http://ar.iiarjournals.org/content/42/1/173.abstract
AB Aim: We evaluated real-world efficacy and toxicity of lenvatinib in 142 patients with advanced hepatocellular carcinoma (HCC) at six tertiary referral centres. Patients and Methods: The patients with advanced HCC treated with lenvatinib were grouped into two categories based on REFLECT criteria for analysis of efficacy and safety. The primary endpoint was progression-free survival (PFS). Results: The objective response rate (ORR) at week 12 of therapy was 41.5%, with a median PFS of 176 days. Child–Pugh score of 5 points, the presence of extrahepatic metastasis and adverse effects grade 2 or higher were considered independent factors associated with both better PFS and ORR. The ORR for patients who fulfilled the REFLECT inclusion criteria was significantly higher than that for those who did not. However, no significant differences in PFS were observed between the two groups. The incidence rate of adverse effects grade 3 or higher was 40.1%, which was similar for the two groups. Conclusion: Lenvatinib is safe and effective for patients, whether or not they satisfy REFLECT criteria. The result warrants replication in a larger study.